Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRNDO-03
- Development stage
- Preclinical
- Lead developer
- Sirius Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
SRNDO-03 is a pre-clinical small interfering RNA (siRNA) therapeutic candidate being developed by Sirius Therapeutics for the treatment of obesity. The drug is part of a pipeline of RNA-based therapies that leverage the company's proprietary delivery technology to target specific tissues, including the liver, adipose tissue, heart, kidney, and the central nervous system (CNS). While the specific molecular target of SRNDO-03 remains undisclosed, the therapy aims to modulate metabolic pathways through gene silencing. It is currently in the IND-enabling/pre-clinical phase of development.
Beyond the preview
Go deeper on SRNDO-03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SRNDO-03.